Braingaze signs an agreement with an American company to commercialize a digital diagnostic solution for attention deficit hyperactivity disorder
The University of Barcelona (UB) digital cognitive health spin-off, Braingaze, and Tris Pharma, Inc., a commercial-stage biopharmaceutical company focused on ADHD, pain, addiction and neurological disorders, have signed a licensing agreement that grants the American company the exclusive rights to market Braingaze’s ADHD digital diagnostic platform in the United States and Canada.
Braingaze’s digital ADHD diagnostic tool, the first of its kind based on biomarkers, has been developed and validated in Europe and obtained CE marking as a medical device in 2016. With input from the US Food and Drug Administration In the United States (FDA), Tris Pharma will conduct clinical trials in the United States to further validate Braingaze’s technology as an ADHD diagnostic tool for clinical use in the United States and Canada.
“Patients and clinicians need more objective and validated tools to support accurate diagnoses of ADHD beyond current subjective assessments,” said Ketan Mehta, founder and CEO of Tris Pharma. He added: “As part of our long-term commitment to significantly advance care for people with this disorder, Tris believes we have an obligation to help address that important diagnostic need. “The Braingaze technology and its clinical results suggest it could be an ideal solution.”
The number of digital health products for mental disorders, including ADHD, has skyrocketed in recent years as the COVID-19 pandemic led to significant investments in this area. Braingaze’s digital technology, based on biomarkers and enhanced with AI, is designed to help diagnose ADHD in children and adults. It consists of a computer game and patented eye-tracking technology to measure individuals’ attention. From these measurements, the test provides doctors with ADHD probability and severity scores for each patient.
“We have received enthusiastic feedback from European doctors who tell us that our new diagnostic test is an improvement over the subjective tools they have had to rely on until now,” said Laszlo Bax, CEO and co-founder of Braingaze. “We are delighted to partner with Tris, another leader in the ADHD space that has an exceptional track record with four marketed medications, to expand the reach of our ADHD diagnostic solutions to patients we can benefit from in the United States and Canada.”
On the other hand, the president of the Tris Pharma Brand Division, James Hackworth, highlighted that: “Tris analyzed multiple digital ADHD diagnostic technologies in the investigational phase and concluded that the Braingaze test substantially outperforms other tools. designed to provide an objective evaluation and diagnosis of ADHD.”
And he concluded: “We look forward to validating this technology in US patients, with the goal of providing patients, their caregivers, and healthcare providers with greater confidence in ADHD diagnoses to support improved outcomes.”